Is non-alcoholic fatty liver disease a prothrombotic risk factor?

Submitted: 16 April 2023
Accepted: 28 April 2023
Published: 19 May 2023
Abstract Views: 422
PDF: 124
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Niccolò Bitto niccolo.bitto@unimi.it https://orcid.org/0000-0002-5667-6857 Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Ca’ Granda Foundation, Ospedale Maggiore Policlinico, Milan, Italy.
  • Vincenzo La Mura Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Ca’ Granda Foundation, Ospedale Maggiore Policlinico, Milan; Department of Pathophysiology and Transplantation, University of Milan, Italy.
  • Anna Ludovica Fracanzani Department of Pathophysiology and Transplantation, University of Milan; Unit of Internal Medicine and Metabolic Disease, IRCCS Ca’ Granda Foundation, Ospedale Maggiore Policlinico, Milan, Italy.
  • Armando Tripodi https://orcid.org/0000-0003-1602-2776 Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Ca’ Granda Foundation, Ospedale Maggiore Policlinico, Milan; Luigi Villa Foundation, Milan, Italy.

Not available

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Plaudit

Ajmera V, Cepin S, Tesfai K, et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol. 2022; Available from: https://www.sciencedirect.com/science/article/pii/S0168827822033025 DOI: https://doi.org/10.1016/j.jhep.2022.11.010
Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Amp Hepatol. 2013; 10:330–45. DOI: https://doi.org/10.1038/nrgastro.2013.41
Stine JG, Argo CK, Pelletier SJ, et al. Advanced non-alcoholic steatohepatitis cirrhosis: A high-risk population for pre-liver transplant portal vein thrombosis. World J Hepatol. 2017; 9:139–46. DOI: https://doi.org/10.4254/wjh.v9.i3.139
Tripodi A, Fracanzani AL, Primignani M, et al. Procoagulant imbalance in patients with non-alcoholic fatty liver disease. J Hepatol. 2014; 61:148–54. DOI: https://doi.org/10.1016/j.jhep.2014.03.013
Tripodi A. Detection of procoagulant imbalance. Modified endogenous thrombin potential with results expressed as ratio of values with-to-without thrombomodulin. Thromb Haemost. 2017; 117:830–6. DOI: https://doi.org/10.1160/TH16-10-0806
Potze W, Siddiqui MS, Boyett SL, Adelmeijer J, et al. Preserved hemostatic status in patients with non-alcoholic fatty liver disease. J Hepatol. 2016; 65: 980–7. DOI: https://doi.org/10.1016/j.jhep.2016.06.001
Cerletti C, Colucci M, Storto M, Semeraro F, et al. Randomised trial of chronic supplementation with a nutraceutical mixture in subjects with non-alcoholic fatty liver disease. Br J Nutr. 2020; 123:190–7. DOI: https://doi.org/10.1017/S0007114519002484
Valenti L, Tripodi A, La Mura V, et al. Clinical and genetic determinants of the fatty liver-coagulation balance interplay in individuals with metabolic dysfunction. JHEP Rep. 2022; 4:100598. DOI: https://doi.org/10.1016/j.jhepr.2022.100598
Paolini E, Longo M, Corsini A, Dongiovanni P. The Non-Invasive Assessment of Circulating D-Loop and mt-ccf Levels Opens an Intriguing Spyhole into Novel Approaches for the Tricky Diagnosis of NASH. Int J Mol Sci. 2023; 24:23-31. DOI: https://doi.org/10.3390/ijms24032331
Pasarín M, La Mura V, Gracia-Sancho J, et al. Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD. PloS One. 2012; 7:e32785. DOI: https://doi.org/10.1371/journal.pone.0032785
Tripodi A, Lombardi R, Primignani M, et al. Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences. Biomedicines. 2022; 10:249. DOI: https://doi.org/10.3390/biomedicines10020249
Kopec AK, Joshi N, Towery KL, et al. Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice. J Pharmacol Exp Ther. 2014; 351:288–97. DOI: https://doi.org/10.1124/jpet.114.218545

How to Cite

Bitto, N., La Mura, V., Fracanzani, A. L., & Tripodi, A. (2023). Is non-alcoholic fatty liver disease a prothrombotic risk factor?. Bleeding, Thrombosis and Vascular Biology, 2(2). https://doi.org/10.4081/btvb.2023.81